Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating restated by analysts at B. Riley Financial in a research report issued on Monday,Benzinga reports. They currently have a $12.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $17.00. B. Riley Financial’s price target points to a potential upside of 144.65% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright dropped their price objective on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a report on Monday. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $13.70.

Check Out Our Latest Report on VNDA

Shares of VNDA traded down $0.10 on Monday, reaching $4.91. 877,616 shares of the company’s stock were exchanged, compared to its average volume of 1,679,127. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $294.96 million, a P/E ratio of -1.06 and a beta of 0.64. The business has a 50 day moving average price of $5.78 and a two-hundred day moving average price of $6.75. Vanda Pharmaceuticals has a 12 month low of $4.15 and a 12 month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The business had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Research analysts anticipate that Vanda Pharmaceuticals will post -2.2 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Vanda Pharmaceuticals during the second quarter worth about $46,841,000. Renaissance Technologies LLC raised its position in shares of Vanda Pharmaceuticals by 11.2% during the first quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock worth $25,979,000 after purchasing an additional 378,598 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock valued at $17,900,000 after purchasing an additional 14,336 shares in the last quarter. AIGH Capital Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock valued at $19,002,000 after purchasing an additional 751,569 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

(Get Free Report)

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

• Five stocks we like better than Vanda Pharmaceuticals
• 3 Dividend Champion Utilities for a Market That Can’t Sit Still
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington
• 5 Stocks the Market Rewarded After Strong Earnings Results

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Head-To-Head Survey: Plug Power (NASDAQ:PLUG) vs. Electrovaya (OTCMKTS:EFLVF)

Top Leisure Stocks To Follow Now – August 10th